Low Molecular Weight Heparin (Enoxaparin) Versus Oral Anticoagulant Therapy (Acenocoumarol) in the Long-Term Treatment of Deep Venous Thrombosis in the Elderly: a Randomized Trial

 

 Buy Article Permissions and Reprints

Summary

This study aims to establish the relative effectiveness and safety of low molecular weight heparin in elderly patients with venous thrombosis in order to find an alternative to oral anticoagulant therapy with less bleeding complications in the long-term treatment of deep venous thrombosis (DVT).

One hundred consecutive elderly patients (>75 years old) with venographically demonstrated proximal DVT were included in a randomized trial. All patients were treated for ten days with adjusted doses of intravenous heparin. Informed consent was obtained and on the eight day, patients were randomly allocated to receive acenocoumarol (INR 2.0-3.0) or subcutaneous enoxaparin (4000 anti-Xa units once a day) for three months. All patients were followed-up clinically and venographically for a one year period. The results were analyzed with Fisher’s exact test or chi-square test as appropriate.

During the treatment and surveillance period, 6 of the 50 patients (12%) who received acenocoumarol and 8 of the 50 patients (16%) who received enoxaparin had new episodes of venous thromboembolism confirmed by objective testing (p = 0.6; 95% CI for the difference: −19.5 to 11.5). Hemorrhagic complications occurred in six of the 50 patients (12%) who received acenocoumarol and in one (2%) of those on enoxaparin (p = 0.1; 95% CI for the difference: -1.8 to 21.8). Vertebral fractures developed in 2 patients (4%) in the enoxaparin group (p = 0.5; 95% CI for the diference: −11.4 to 3.4).

These results show that fixed dose enoxaparin seems to be effective and safe in the long-term treatment of proximal DVT in the elderly. In comparison with oral anticoagulants, the findings are inconclusive due to the wide confidence intervals for differences between outcomes, however they suggest that the former may have less bleeding complications with similar efficacy.

^* F. Veiga is presently Head of Department of Geriatrics, Complexo Hospitalario Xeral-Calde, Lugo, Spain.

• References

• 1 Hull RD, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-81.
  CrossrefPubMedGoogle Scholar
• 2 Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114 (Suppl. 05) 511S-23S.
  CrossrefPubMedGoogle Scholar
• 3 Hull RD, Delmore T, Carter C, Hirsh J, Genton E, Gent M, Turpie G, McLaughlin D. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982; 306: 189-94.
  CrossrefPubMedGoogle Scholar
• 4 Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, Tapson V. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114 (Suppl. 05) 561S-78S.
  CrossrefPubMedGoogle Scholar
• 5 Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
  PubMedGoogle Scholar
• 6 Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, Tagliaferri A, Dettori AG. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-7.
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Das SK, Cohen AT, Edmondson RA, Melissari A, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-7.
  CrossrefPubMedGoogle Scholar
• 8 Lopaciuk S, Bielska-Falda H, Noszczyk W, Bielawiec M, Witkiewicz W, Filipecki S, Michalak J, Ciesielski L, Mackiewicz Z, Czestochowska E, Zawilska K, Cencora A. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 1999; 81: 26-31.
  Article in Thieme ConnectPubMedGoogle Scholar
• 9 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 Harenberg J, Huhle G, Piazolo L, Giese C, Heene DL. Long-term anticoagulation of outpatients with adverse events to oral anticoagulants using lowmolecular-weight heparin. Semin Thromb Hemost 1997; 23: 167-72.
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
  CrossrefPubMedGoogle Scholar
• 12 Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-9.
  CrossrefPubMedGoogle Scholar
• 13 PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the prospective investigation of pulmonary embolism diagnosis (PIOPED). JAMA 1990; 263: 2753-9.
  CrossrefPubMedGoogle Scholar
• 14 Katz S, Ford AB, Moskowitz RW, Jackson BA, Jaffe MW. Studies of illness in the aged. JAMA 1963; 185: 914-9.
  CrossrefPubMedGoogle Scholar
• 15 Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res 1975; 12: 189-98.
  CrossrefPubMedGoogle Scholar
• 16 Hull RD, Carter CJ, Jay RM, Ockelford PA, Hirsh J, Turpie AG, Zielinsky A, Gent M, Powers PJ. The diagnosis of acute, recurrent, deep-vein thrombosis: a diagnostic challenge. Circulation 1983; 67: 901-6.
  CrossrefPubMedGoogle Scholar
• 17 Weinmann EE, Salzman EW. Deep vein thrombosis. N Engl J Med 1994; 331: 1630-41.
  CrossrefPubMedGoogle Scholar
• 18 Hull RD, Delmore T, Genton E, Hirsh J, Gent M, Sackett D, McLoughlin D, Armstrong P. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979; 301: 855-8.
  CrossrefPubMedGoogle Scholar
• 19 Hirsh J. The optimal duration of anticoagulant therapy for venous thrombosis. N Engl J Med 1995; 332: 1710-1.
  CrossrefPubMedGoogle Scholar
• 20 Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson DR, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
  CrossrefPubMedGoogle Scholar
• 21 Schulman S. Long-term prophylaxis in venous thromboembolism: LMWH or oral anticoagulation?. Haemostasis 1998; 28 (Suppl. 03) 17-21.
  PubMedGoogle Scholar
• 22 Gallus AS, Jackaman J, Tillet J, Mills V, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986; 02: 1293-6.
  PubMedGoogle Scholar
• 23 Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, Hirsh J, Martin GJ, Green D. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322: 1260-4.
  CrossrefPubMedGoogle Scholar
• 24 Research Committee of the British Thoracic Society. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Lancet 1992; 340: 873-6.
  PubMedGoogle Scholar
• 25 Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH. Risk factors for complications of chronic anticoagulation. Warfarin Optimized Outpatient Follow-up Study Group. Ann Intern Med 1993; 118: 511-20.
  CrossrefPubMedGoogle Scholar
• 26 Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, Loogna E, Svensson E, Ljungberg B, Walter H. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332: 1661-5.
  CrossrefPubMedGoogle Scholar
• 27 Melton III LJ, Kan SH, Frye MA, Wahner HW, O’Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol 1989; 129: 1000-11.
  CrossrefPubMedGoogle Scholar